Target Name: GFRA1
NCBI ID: G2674
Review Report on GFRA1 Target / Biomarker Content of Review Report on GFRA1 Target / Biomarker
GFRA1
Other Name(s): RET1L | RETL1 | GDNF family receptor alpha-1 (isoform b) | TAT 193 | GDNF receptor alpha-1 | GFRalpha-1 | GDNF receptor alpha 1e | GDNF family receptor alpha-1 (isoform a) | GFRA1 variant 1 | GFRA1 variant 2 | GDNFRA | GDNFR | GDNF family receptor alpha 1, transcript variant 2 | GDNFR-alpha-1 | TGF-beta related neurotrophic factor receptor 1 | PI-linked cell-surface accessory protein | GDNF family receptor alpha-1 | TGF-beta-related neurotrophic factor receptor 1 | GFR-ALPHA-1 | RHDA4 | GFR-alpha-1 | RET ligand 1 | GPI-linked anchor protein | GDNF family receptor alpha 1, transcript variant 1 | GDNF family receptor alpha 1 | Glial cell line-derived neurotrophic factor receptor alpha | GDNF receptor alpha 1d | TRNR1 | GFRA1_HUMAN

GFRA1 Regulates TGF-β and Promotes Cell Health

GFRA1 (Guanosine Familial Research Association 1) is a protein that is expressed in almost all tissue cells, including brain, heart, liver, and muscle. It is a key regulator of cell growth, differentiation, and survival, and is involved in many important cellular processes. GFRA1 has also been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of GFRA1 is its role as a negative regulator of the TGF-β pathway. TGF-β is a cytokine that plays a central role in cell growth, differentiation, and survival, and is involved in many important cellular processes, including cell division, gene expression, and angiogenesis. However, TGF-β can also promote the development of cancer and other diseases, and is often considered as a potential drug target.

GFRA1 is a key regulator of TGF-β activity, and has been shown to play a critical role in preventing the negative effects of TGF-β on cellular processes. GFRA1 has been shown to inhibit the activity of TGF-β, and to regulate the levels of TGF-β proteins in cells. This helps to prevent TGF-β from promoting the development of cancer and other diseases.

In addition to its role in TGF-β regulation, GFRA1 is also involved in the regulation of many other cellular processes. For example, GFRA1 has been shown to be involved in the regulation of cell adhesion, cell migration, and the production of extracellular matrix (ECM) proteins. GFRA1 has also been shown to play a role in the regulation of the cytoskeleton, and has been shown to influence the formation and stability of actin filaments in cells.

GFRA1 has also been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, GFRA1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. shown to be involved in the development of certain autoimmune disorders, such as rheumatoid arthritis and Crohn's disease.

In conclusion, GFRA1 is a protein that is expressed in nearly all tissue cells, and is involved in many important cellular processes. GFRA1 plays a key role in the regulation of TGF-β activity, and has been shown to prevent the negative effects of TGF-β on cellular processes. GFRA1 is also involved in the regulation of many other cellular processes, and has been implicated in a number of diseases. Therefore, GFRA1 is a potential drug target for the treatment of a wide range of diseases.

Protein Name: GDNF Family Receptor Alpha 1

Functions: Receptor for GDNF. Mediates the GDNF-induced autophosphorylation and activation of the RET receptor (By similarity)

The "GFRA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GFRA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GFRA2 | GFRA3 | GFRA4 | GFRAL | GFUS | GGA1 | GGA2 | GGA3 | GGACT | GGCT | GGCX | GGH | GGN | GGNBP1 | GGNBP2 | GGPS1 | GGT1 | GGT2P | GGT3P | GGT5 | GGT6 | GGT7 | GGT8P | GGTA1 | GGTLC1 | GGTLC2 | GGTLC3 | GH1 | GH2 | GHDC | GHITM | GHR | GHRH | GHRHR | GHRL | GHRLOS | GHSR | GID4 | GID8 | GIGYF1 | GIGYF2 | GIHCG | GIMAP1 | GIMAP1-GIMAP5 | GIMAP2 | GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3 | GJD4 | GK | GK2 | GK3 | GK5 | GKAP1 | GKN1 | GKN2 | GKN3P | GLA | GLB1 | GLB1L | GLB1L2